Abivax Shares Dip Despite Strong Annual Performance Amid Speculative Fluctuations
Abivax shares experienced a decline at the opening on Tuesday, December 16, 2025, despite a strong annual performance and a promising therapeutic outlook.
Market Reaction to Quarterly Financial Results
Abivax shares fell by 5.47% on Tuesday, December 16, opening at 98.50 euros compared to the previous day's close of 104.20 euros. This drop followed the announcement of the financial results for the third quarter of 2025. Trading volumes were low, with only 0.02% of the capital traded, indicating investor caution due to increased losses. Despite this, the stock has shown an exceptional annual performance of 1,280%, driven by the therapeutic promise of obefazimod. This trend is part of a broader fundamental reevaluation since the publication of positive phase 3 results in July. Over three months, the stock has gained 37.38%, although the weekly performance has been slightly negative at -1.4%, reflecting a consolidation phase after speculative surges in early December due to rumors of a takeover by pharmaceutical giant Eli Lilly.
Financial Position and Performance Analysis
As of September 30, 2025, the biotechnology company reported a cash position of 589.7 million euros, providing financial autonomy until the fourth quarter of 2027. This strong position primarily resulted from a fundraising event in July 2025 on the Nasdaq, which raised a net amount of 597.2 million euros. For the first nine months of 2025, the net loss reached 254.1 million euros, a significant increase from the 136.9 million euros recorded in the same period last year. Operating loss stood at 174.4 million euros compared to 130.2 million euros a year earlier, mainly reflecting increased research and development expenses, which rose to 133.4 million euros due to programs focusing on ulcerative colitis and Crohn's disease. General and administrative expenses also increased by 16.5 million euros, partly due to social charges related to the stock price increase in the third quarter. The financial result recorded a loss of 79.7 million euros, affected by the rise in the fair value of convertible bonds and exchange losses.
Technical Analysis and Market Sentiment
The price of 98.50 euros is above the 50-day moving average of 92.34 euros, confirming the maintenance of an underlying bullish trend despite the day's decline. The gap is even more significant with the 200-day moving average at 43.91 euros, indicating the extent of the revaluation since the beginning of the year. The RSI at 46 is in the neutral zone, suggesting that the stock has absorbed some of the overheating observed in previous speculative sessions, providing technical leeway before reaching an oversold zone. Bollinger Bands frame the stock between a support at 91.82 euros and a resistance at 117.52 euros, with the price currently moving in the middle of this channel. The MACD shows a slightly negative histogram at -0.09, with the MACD line at 3.96 just below the signal line at 4.06, indicating a slowdown in momentum in the very short term without invalidating the long-term dynamic. The one-month volatility of 21.74% reflects significant fluctuations typical of biotechnological stocks in advanced clinical trial phases, amplified by recurring speculations about a potential acquisition by a major pharmaceutical company. With a negative beta of -0.16, Abivax shows almost total decorrelation with the CAC 40, explaining its ability to progress independently in an uncertain market environment.
